SCHEMBL18539734

SCHEMBL18539734

CCOCc1nc(-c2ccccc2)ncc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 2/20 0.55
MAPK1 P28482 1/20 0.55
ATM Q13315 1/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
TP53 P04637 1/20 0.54
MEN1 O00255 8/20 0.52
KMT2A Q03164 8/20 0.52
CYP1A2 P05177 4/20 0.51
POLB P06746 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 2/20 0.49
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18539732 0.88 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18549679 0.83 MEN1 (0.49) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18550813 0.80 MEN1 (0.46) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18539741 0.80 MEN1 (0.44) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18539740 0.79 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL3564909 0.78 MEN1 (0.52) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18549304 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL3576827 0.76 PDE4B (0.54) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18550879 0.75 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18539736 0.75 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION ASAHI GLASS COMPANY, LIMITED (JP) 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION CYP2B6, PFAS, CYP2F1 ALDH1A1 1430/4885SMN1; SMN2 4379/4885MAPT 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.